Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
扎努布替尼、奥妥珠单抗和维奈克拉用于一线治疗TP53突变型套细胞淋巴瘤
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024025563
Kumar, Anita; Soumerai, Jacob; Abramson, Jeremy S; Barnes, Jeffrey A; Caron, Philip; Chhabra, Shalini; Chabowska, Maria; Dogan, Ahmet; Falchi, Lorenzo; Grieve, Clare; Haydu, J Erika; Johnson, Patrick Connor; Joseph, Ashlee; Kelly, Hailey E; Labarre, Alyssa; Lue, Jennifer Kimberly; Martignetti, Rosalba; Mi, Joanna; Moskowitz, Alison; Owens, Colette; Plummer, Sean; Puccio, Madeline; Salles, Gilles; Seshan, Venkatraman; Simkins, Elizabeth; Slupe, Natalie; Zhang, Honglei; Zelenetz, Andrew D
